Old Web
English
Sign In
Acemap
>
authorDetail
>
Montse Querolt
Montse Querolt
Pi
Antibody
Immunology
Medicine
Phases of clinical research
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)
2020
The Journal of Allergy and Clinical Immunology
H. James Wedner
John W. Sleasman
William R. Lumry
Iftikhar Hussain
James B. Harris
Elsa Mondou
Jiang Lin
Carrie Hames
Montse Querolt
Mark R Stein
Show All
Source
Cite
Save
Citations (0)
Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study
2020
The Journal of Allergy and Clinical Immunology
John W. Sleasman
William R. Lumry
Iftikhar Hussain
H. James Wedner
James B. Harris
Elsa Mondou
Jiang Lin
Carrie Hames
Montse Querolt
Mark R. Stein
Show All
Source
Cite
Save
Citations (0)
1